Single-center comparison of the efficacy and complications of arterial vascular closure devices in interventional radiology

医学 血管闭合器 止血 介入放射学 外科 回顾性队列研究 放射科
作者
Matthew Elmasri,Stephen T. Kee,John M. Moriarty,Antoinette S. Gomes,Edward W. Lee,J. McWilliams
出处
期刊:Journal of Vascular Access [SAGE]
卷期号:18 (4): 339-344 被引量:7
标识
DOI:10.5301/jva.5000623
摘要

Vascular closure devices (VCDs) are commonly used to achieve hemostasis of arterial access sites, but there is little comparative data on the variety of VCDs currently in clinical use. We reviewed the VCD experience at our institution to determine the safest and most effective VCD.Retrospective analysis of 907 consecutive arterial procedures in interventional radiology from June 2012 to June 2014 was performed. Five VCDs were used: Angio-Seal (n = 478), FISH (n = 56), Mynx (n = 56), Perclose (n = 61), and Starclose (n = 68). Patients who underwent manual compression (n = 188) without use of VCDs were also studied as a comparison group. Patient demographics and pre-procedural laboratory parameters were recorded. The technical success rate for achievement of hemostasis and complication rates were noted.Complete hemostasis rate (aka technical success rate) was 93.5% for Angio-Seal, 83.9% for FISH, 53.6% for Mynx, 73.7% for Perclose, 76.5% for Starclose, and 91.5% for manual compression. The differences among the devices were statistically significant (p<0.001). Fourteen major complications (1.5%) were encountered: nine with Angio-Seal (1.9%), one with Mynx (1.8%), one with Starclose (1.5%), and three with manual compression (1.6%); these differences were not statistically significant. Of the demographic and laboratory parameters studied, none were significantly correlated with hemostasis failure or development of complications.In our single-center institutional experience, Angio-Seal is the device with the best technical success rate. Major complications of VCDs were rare, with no statistically significant difference between devices.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jun完成签到,获得积分10
刚刚
1秒前
和谐桐完成签到,获得积分10
1秒前
赘婿应助zzj采纳,获得10
2秒前
2秒前
2秒前
orixero应助闫晓涵采纳,获得10
4秒前
华仔应助freeee采纳,获得10
4秒前
蟹黄堡秘方应助gao采纳,获得10
4秒前
5秒前
留白发布了新的文献求助10
5秒前
5秒前
赘婿应助平常初珍采纳,获得10
6秒前
长情孤晴关注了科研通微信公众号
7秒前
qinglingdao发布了新的文献求助10
7秒前
7秒前
8秒前
菜鸟完成签到,获得积分10
8秒前
8秒前
和谐桐发布了新的文献求助10
8秒前
今后应助cc采纳,获得10
8秒前
9秒前
10秒前
带头大哥应助mxm采纳,获得200
10秒前
MHY发布了新的文献求助10
10秒前
乐le发布了新的文献求助10
10秒前
hhhh完成签到 ,获得积分10
11秒前
12秒前
cz完成签到,获得积分20
12秒前
学术蝗虫完成签到,获得积分10
13秒前
科目三应助zt采纳,获得10
13秒前
15秒前
科研通AI6.2应助帅哥采纳,获得10
15秒前
赘婿应助kk采纳,获得10
15秒前
15秒前
善良乐松完成签到,获得积分10
16秒前
盼不热夏完成签到,获得积分10
16秒前
今后应助隐形的蓝天采纳,获得10
17秒前
在水一方应助不渝采纳,获得10
18秒前
情怀应助卡卡采纳,获得10
18秒前
高分求助中
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Propeller Design 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Handbook of pharmaceutical excipients, Ninth edition 1500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6010243
求助须知:如何正确求助?哪些是违规求助? 7554159
关于积分的说明 16132890
捐赠科研通 5156869
什么是DOI,文献DOI怎么找? 2762080
邀请新用户注册赠送积分活动 1740633
关于科研通互助平台的介绍 1633366